



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 24 May 2016 (#15)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) Pre-Awards** (Dr Christa Coetsee cdevries@sun.ac.za) **as soon as possible to inform of your intent to apply and then confirm at least 30 days before the submission date**. The NIH grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.**

Important notices

- Findings of Research Misconduct ([NOT-OD-16-090](#))
- Notice of Intent to Publish a Funding Opportunity Announcement for Human Heredity and Health in Africa (H3Africa): Global Health Bioinformatics Research Training Program (U2R) ([NOT-RM-16-020](#))

1. Partnerships for Structure-Based Design of Novel Immunogens for Vaccine

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(RFA-AI-16-047\)](#)

Type: R01

Application Due Date: October 3, 2016. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from multi-disciplinary teams for milestone-driven research projects that utilize novel, structure-based vaccine design approaches to generate candidate vaccine immunogens against infectious disease pathogens of clinical concern.

Budget: NIAID intends to commit \$6.3 million in FY 2017 to fund 5-10 awards. Budgets for direct costs of up to \$750,000 per year may be requested. Applicants may also request up to an additional \$300,000 in the first year of the award for major equipment to ensure that research objectives can be met and biohazards can be contained, totalling \$1,050,000 direct costs. The scope of the proposed project should determine the project period. The maximum project period is 5 years

2. Mechanisms of Cancer and Treatment-related Symptoms and Toxicities

Letter of Intent due date: N/A

Hyperlink: [\(PA-16-258\)](#)

Type: R21

Application Due Date [Standard dates](#) and [Standard AIDS dates](#) apply by 5:00 PM local time of applicant organization. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) invites innovative pilot projects or feasibility studies to stimulate research aimed to better understand the complex interaction of biological, cognitive, behavioral, and sociocultural factors that contribute to cancer and treatment related symptoms and toxicities throughout the cancer care trajectory. Data from the preliminary studies would be used to validate and extend the findings in larger cohort studies and/or test novel, mechanistically-driven interventions via the R01 funding mechanism. Of particular interest is to gain new insights about these factors, either alone or in combination, in minority, underserved, the elderly, and pediatric and young adult populations. Specifically, the FOA aims to identify, describe, and quantify these factors associated with acute and chronic cancer and treatment related symptoms and toxicities.

Budget: The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

3. Serious Adverse Drug Reaction Research

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-16-274\)](#)
[\(PAR-16-275\)](#)

Type: R21
R01

Application Due Date: October 4, 2016; February 1, 2017; June 1, 2017; October 2, 2017; February 1, 2018; June 1, 2018; October 1, 2018; February 1, 2019; June 3, 2019, and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement is to support research grants that will advance the state of knowledge of serious adverse drug reactions. Applications across the spectrum of research are encouraged.

Budget: R21 - The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

4. Environmental Exposures and Health: Exploration of Non-Traditional Settings

Letter of Intent due date: N/A

Hyperlink: [\(PA-16-263\)](#)
[\(PA-16-273\)](#)

Type: R01
R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this funding opportunity announcement (FOA) is to encourage interdisciplinary research aimed at promoting health, preventing and limiting symptoms and disease, and reducing health disparities across the lifespan for those living or spending time in non-traditional settings (i.e. playgrounds and nursing homes). These settings result in exposure to environmental pollutants and toxins that result in health risks, symptoms, and other health conditions/diseases; including lower respiratory disease, chronic obstructive pulmonary disease, cardiovascular disease, and complex environmental exposures that may be exacerbated by non-chemical stressors encountered in community settings, physiological function of organs and systems of the fetus/child/adolescence, and lower respiratory disease. Risk identification and symptom management include prevention and behavior changes and actions to maintain health and prevent disease with an emphasis on the individual, family, and community which will advance nursing science. For purposes of this FOA, non-traditional settings include, but are not limited to, places such as community centers; pre-school and non-traditional school environments (e.g., churches, daycare, home-based schools, dormitories, alternative schools, and playgrounds); child and older adult foster care facilities; older adult day care facilities; half-way homes; and assisted living and long-term care facilities.

Budget: R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. R21 - The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

5. Methodology and Measurement in the Behavioral and Social Sciences

Letter of Intent due date: N/A

Hyperlink: [\(PAR-16-260\)](#)
[\(PAR-16-261\)](#)

Type: R01
R21

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to invite qualified researchers to submit grant applications aimed at improving and developing methodology in the behavioral and social sciences through innovations in research design, measurement, data collection and data analysis techniques. The participating NIH Institutes and Centers (ICs) encourage research that will improve the quality and scientific power of behavioral and social science data relevant to the IC missions. Applicants are strongly encouraged to contact the Scientific/Research Contact (see Section VII, Agency Contacts) of the IC that most closely matches their research focus to determine IC interest in the proposed research topic.

Budget: R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. R21 - Direct costs are limited to \$275,000 for the total two-year period, with no more than \$200,000 in direct costs allowed in any single year. The maximum project period is 2 years.

6. Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP)

Letter of Intent due date: N/A

Hyperlink: [\(PAR-16-262\)](#)

Type: R01

Application Due Date: January 4, 2017; January 4, 2018; January 4, 2019. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications that address the long term goal and objective of developing sustained release strategies for HIV treatment or prevention. Applications may propose treatment or prevention products delivered using sustained release platforms (oral, injection, implant or direct delivery to HIV target mucosa) that will provide a minimum of 1 week for oral (treatment) or a minimum of once a month for all other drug delivery systems for prevention and treatment protection/efficacy.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

7. Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS

Letter of Intent due date: N/A

Hyperlink: [\(PAR-16-266\)](#)

Type: R01

Application Due Date: [Standard dates](#) Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) invites research grant applications from organizations/institutions that propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 3 years.

8. NIAID Clinical Trial Implementation Grant

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-16-269\)](#)
[\(PAR-16-270\)](#)

Type: R01
U01

Application Due Date: September 13, 2016; January 13, 2017; May 12, 2017; September 13, 2017 January 12, 2018; May 14, 2018; September 13, 2018; January 14, 2019; May 13, 2019, by 5:00 .Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages applications for implementation of investigator-initiated, non-high-risk clinical trials. The trials should be hypothesis-driven, related to the research mission of the NIAID and considered a high priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (<http://www3.niaid.nih.gov/about/whoWeAre/planningPriorities/>). Only one clinical trial may be proposed in each NIAID Clinical Trial Implementation (R01) Grant application.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

9. NIAID Clinical Trial Planning Grant

Letter of Intent due date: 30 days prior to the application due date

Hyperlink: [\(PAR-16-272\)](#)

Type: R34

Application Due Date: September 13, 2016; January 13, 2017; May 12, 2017; September 13, 2017 January 12, 2018; May 14, 2018; September 13, 2018; January 14, 2019; May 13, 2019Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) encourages applications that propose the complete planning, design, and preparation of the documentation necessary for implementation of investigator-initiated clinical trials. The trials should be hypothesis-driven, milestone-defined, related to the research mission of the NIAID and considered high priority by the Institute. Investigators are encouraged to visit the NIAID website for additional information about the research mission and high-priority research areas of the NIAID (<http://www3.niaid.nih.gov/about/whoWeAre/planningPriorities/>).

Budget: Application budgets are limited to \$150,000 direct costs. The scope of the proposed project should determine the project period. The maximum period is one year.

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

DP1 – NIH Director’s Pioneer Award (NDPA): To support individuals who have the potential to make extraordinary contributions to medical research. The NIH Director’s Pioneer Award is not renewable.

DP3 – Institutional Training and Director Program Projects -Type 1 Diabetes Targeted Research Award: To support research tackling major challenges in type 1 diabetes and promoting new approaches to these challenges by scientific teams.

P01 – Research Program Projects: For the support of a broadly based, multidisciplinary, often long-term research program which has a specific major objective or a basic theme. A program project generally involves the organized efforts of relatively large groups, members of which are conducting research projects designed to elucidate the various aspects or components of this objective. Each research project is usually under the leadership of an established investigator. The grant can provide support for certain basic resources used by these groups in the program, including clinical components, the sharing of which facilitates the total research effort. A program project is directed toward a range of problems having a central research focus, in contrast to the usually narrower thrust of the traditional research project. Each project supported through this mechanism should contribute or be directly related to the common theme of the total research effort. These scientifically meritorious projects should demonstrate an essential element of unity and interdependence, i.e., a system of research activities and projects directed toward a well-defined research program goal.

P20 – Research Program Projects and Centers -Exploratory Grant: To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

UH2/UH3 – NIH Phase Innovation Awards Cooperative Agreement: To support the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

U2R – International Research Training Cooperative Agreements: Cooperative agreement mechanism for D43 to support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.

Glossary of selected acronyms:

FOA	Funding Opportunity Announcement
PA	Program Announcements (<i>click on “PA” to search for further funding opportunities</i>)
RFA	Request for Applications (<i>click on “RFA” to search for further funding opportunities</i>)

Complete [Glossary and acronym list of NIH Terms](#)

